Literature DB >> 7670960

Plasminogen activator expression in human atherosclerotic lesions.

F Lupu1, D A Heim, F Bachmann, M Hurni, V V Kakkar, E K Kruithof.   

Abstract

The plasminogen activator (PA) system may participate in the pathogenesis of atherosclerosis by modulating the turnover of intimal fibrin and extracellular matrix deposits and by contributing to intimal cell migration. We present an analysis of tissue-type PA (tPA) and urokinase-type PA (uPA) expression at three levels: mRNA by in situ hybridization, antigen by immunohistochemistry, and enzymatic activity by histoenzymology and zymography. For PA colocalization with cellular or matrix components, we used double immunofluorescence labeling in conjunction with confocal microscopy. In normal arteries, tPA antigen and mRNA were detected in endothelial cells and smooth muscle cells (SMCs). In atherosclerotic arteries, tPA antigen and mRNA were increased in intimal SMCs and in macrophage-derived foam cells of fibro-fatty lesions. Part of the tPA was detected in the extracellular space and colocalized with fibrin deposits. uPA antigen and mRNA were detected in association with the intimal macrophages and SMCs. A particularly high uPA expression was noted on macrophages localized on the rims of the necrotic core. Moreover, using a novel histoenzymological assay as well as classic zymography, we revealed uPA-dependent lytic activity in the advanced lesions, whereas in normal arteries, only tPA-dependent activity was detected, mainly over the vasa vasorum. Also, strong tPA and uPA staining was detected in neomicrovessels of the plaques, suggesting that PAs may play a role in plaque angiogenesis. Our results suggest a local dynamic process of PA-dependent proteolysis in lesion areas that is associated with macrophages and SMCs. A better comprehension of these proteolytic mechanisms in advanced atherosclerotic plaques may provide the basis for therapeutic approaches for plaque stabilization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670960     DOI: 10.1161/01.atv.15.9.1444

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

1.  Proteinases in cardiovascular aneurysms and rupture: targets for therapy?

Authors:  P Carmeliet
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.

Authors:  Seema A Kothari; Mytrang K Le; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

3.  Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

Authors:  Alexander Kapustin; Victoria Stepanova; Natalia Aniol; Douglas B Cines; Alexei Poliakov; Serge Yarovoi; Tatiana Lebedeva; Robin Wait; Grigory Ryzhakov; Yelena Parfyonova; Yaroslav Gursky; Hiromi Yanagisawa; Mikhail Minashkin; Robert Beabealashvilli; Alexander Vorotnikov; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2012-04-15       Impact factor: 3.857

4.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice.

Authors:  Jie Hong Hu; Liang Du; Talyn Chu; Goro Otsuka; Nagadhara Dronadula; Mia Jaffe; Sean E Gill; William C Parks; David A Dichek
Journal:  Circulation       Date:  2010-03-29       Impact factor: 29.690

6.  Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment.

Authors:  Xiuqin Li; Yong Gao; Zhaoyun Meng; Cui Zhang; Qinde Qi
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

7.  Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; J L Degen
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

8.  Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; T H Bugge; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

9.  Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth.

Authors:  Marten Falkenberg; Clifford Tom; Mary Beth DeYoung; Shan Wen; Ruth Linnemann; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling.

Authors:  Nicoleta L Popa; Jon E Wergedal; K-H William Lau; Subburaman Mohan; Charles H Rundle
Journal:  J Bone Miner Metab       Date:  2013-05-23       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.